CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?

Similar documents
GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali

Treatment of Helicobacter pylori Infection

PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School

Peptic Ulcer Disease Update

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

Peptic ulcer disease Disorders of the esophagus

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011

Case 4: Peptic Ulcer Disease. Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie

Treating H. pylori in 2016

Prevpac Pylera Omeclamox-Pak

Management of Dyspepsia

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018

Drug Class Monograph

Epidemiology of Peptic Ulcer Disease

Management of dyspepsia and of Helicobacter pylori infection

American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection

- Ali Yaghi. - Sara Yaghi. - Alia Shatnawi. 1 P a g e

Gastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D

What Is Peptic Ulcer Disease?

Copy right protected Page 1

Index. Note: Page numbers of article titles are in boldface type.

Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師

High use of maintenance therapy after triple therapy regimes in Ireland

EDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.

What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?

Corporate Medical Policy

Helicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA

SELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY

Abdominal Pain in a Young Aviator

Disclosures. Co-founder and Chief Science Officer, TechLab

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group)

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated

National Digestive Diseases Information Clearinghouse

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection

Peptic ulcer disease. Nomin-Erdene. D SOM-531

QUICK QUERIES. Topical Questions, Sound Answers

Management of dyspepsia in adults in primary care

Second Asia Pacific Consensus Guidelines for Helicobacter pylori infection

Low Dose Furazolidone for Eradication of H- pylori Instead of Clarithromycin: A Clinical Trial

Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection

AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee

Peptic ulcer disease: an update on diagnosis and treatment

HELICOBACTER PYLORI UPDATE

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.

Chapter 63 Drugs Used in the Treatment of Gastrointestinal Diseases

Peptic Ulcer Disease & Gastritis Michel-Jose Charles, MD

Proton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

GI update. Common conditions and concerns my patients frequently asked about

Magaji et al., Afr. J. Infect. Dis. 2(2): THE ROLE OF AN AGGRESSIVE FACTOR IN PEPTIC ULCER DISEASE (PUD)

Peptic Ulcer Disease and NSAIDs

Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist

Clinical Policy: Helicobacter Pylori Serology Testing Reference Number: CP.MP.153

PREVENTING ASPIRIN-RELATED ULCER COMPLICATIONS

NSAIDs: Side Effects and Guidelines

Tocilizumab Guided Questionnaire Gastrointestinal Perforation and Related Events

Urea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013

Second term/

Helicobacter pylori:an Emerging Pathogen

Bleeds in Cardiovascular Disease

1. Appropriateness of Gastroscopy: Dyspepsia 1

Treatment and Screening of H. pylori Infection in Alaskan Populations

Helicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease

Helicobacter pylori eradication an update on the latest therapies

Lab:2 Drugs acting on Gastrointestinal tract

TECHNOLOGY OVERVIEW: PHARMACEUTICALS

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

Clinical guideline Published: 3 September 2014 nice.org.uk/guidance/cg184

GI Pearls and Diagnostic Errors

Sequioa Education Systems, Inc. 1

PLANNING COMMITTEE. Seek simplicity, and mistrust it. Alfred North Whitehead

Gastritis General standpoints

Emergency Operations for Bleeding Duodenal Ulcer:A simple option to consider Case Report Abstract Key words Case Report

Duodenal Ulcer / Duodenitis

Use of NSAIDs and infection with Helicobacter pylori what does the rheumatologist need to know?

Efficacy of standard triple therapy versus bismuth-based quadruple therapy for eradication of Helicobacter Pylori infection

The significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus

Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding Patients

The long-term management of patients with bleeding duodenal ulcers

Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU

Pharmacology. Drugs that Affect the Gastrointestinal System

ÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ

OPEN ACCESS TEXTBOOK OF GENERAL SURGERY

Clinical Policy Title: Noninvasive testing for H. pylori

Clinical Policy Title: Noninvasive testing for H. pylori

Proton Pump Inhibitor De-prescribing Guidance

Helicobacter and gastritis

Peptic Ulcer Disease Today

Chapter 14: Training in Radiology. DDSEP Chapter 1: Question 12

Helicobacter pylori Eradication in Patients with an Iatrogenic Ulcer after Endoscopic Resection and Peptic Ulcer

Transcription:

CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory drugs (NSAIDs) C. Stress-related mucosal damage D. Helicobacter pylori infection E. All of the above are common causes of PUD 2. Which of the following is a complication of PUD? A. GI bleeding B. Perforation C. Obstruction D. All of the above 3. Which of the following is an indication for stress ulcer prophylaxis (SUP) in critically ill patients according to the 1999 American Society of Health-System Pharmacists (ASHP) published guidelines? A. Mechanical ventilation for longer than 48 hours B. Patients admitted to telemetry for heart failure C. Platelet count greater than 50,000/mm 3 (50 10 9 /L) but less than 150,000/mm 3 (150 10 9 /L) D. Thermal injuries to more than 15% of body surface area E. Admission to ICU on enteral feedings 4. Which of the following is an important mechanism of prostaglandin mucosal protection?

A. Stimulation of both mucus and phospholipid production B. Promotion of bicarbonate secretion C. Increased mucosal cell turnover D. All of the above 5. A 65-year-old woman presents with new onset epigastric pain, recent 10-pound (4.5kg) weight loss, and anemia. What diagnostic test should this patient undergo? A. Urea breath test B. Stool antigen testing for H. pylori C. Esophagogastroduodenoscopy (EGD) D. H. pylori serology testing E. Manometry 6. A prophylactic medication regimen to prevent NSAID-induced ulcers would not be recommended in: A. A 65-year-old patient on long-term NSAID therapy for osteoarthritis B. A 60-year-old patient on aspirin therapy for cardioprotection C. A 72-year-old patient with history of GI bleeding on NSAID therapy for osteoarthritis D. A 30-year-old patient who takes NSAID for occasional tension headaches E. An 80-year-old patient on high-dose corticosteroids for lupus and history of GI bleeding 7. A preferred first-line option for treating a newly diagnosed patient with H. pylori infection and a penicillin allergy is: A. A triple-drug regimen consisting of a proton pump inhibitor (PPI), clarithromycin and tetracycline

B. A triple-drug regimen consisting of a PPI, levofloxacin, and tetracycline C. A quadruple-drug regimen with bismuth subsalicylate, metronidazole, tetracycline, and a PPI D. Dual therapy consisting of a PPI and metronidazole 8. Which one of the following should be considered when evaluating a patient who has failed H. pylori eradication therapy? A. Patient adherence B. Preexisting antimicrobial resistance C. Potential reinfection D. All of the above 9. Which of the following tests can be used to confirm eradication of H. pylori? A.Urea breath test B. Stool antigen assay C. EGD with biopsies D.Serologic testing E. Both A and D 10. Which of the following statements is true regarding misoprostol? A. Misoprostol is a synthetic prostacyclin analog that exogenously replaces prostacyclin stores B. Misoprostol is safe to use in pregnancy C. Misoprostol is indicated for reducing the risk of H. pylori-induced gastric ulcer

D. Misoprostol is limited by a high frequency of GI side effects E. Misoprostol is the drug of choice for stress ulcer prophylaxis 11. Which of the following is an independent risk factor for the development of NSAID-induced peptic ulcers? A. Concomitant use of corticosteroids B. Alcohol consumption C. Concomitant use of selective serotonin receptor inhibitors (SSRIs) D. Smoking E. All of the above 12. Which one of the following statements is true regarding H. pylori antimicrobial resistance? A. Metronidazole resistance is more prevalent in North America than in Asia B. Clarithromycin resistance occurs in approximately 10% of H. pylori isolates C. Amoxicillin and tetracycline resistance occur in most H. pylori isolates D. Antimicrobial resistance with H. pylori is not a concern 13. In which of the following situations is confirmation of H. pylori eradication recommended? A. Patients who have undergone resection for early gastric cancer B. Patients with gastric MALT lymphoma C. Patients with persistent symptoms after H. pylori treatment D. None of the above E. All of the above 14. Which of the following is not a goal of PUD therapy? A. Resolve symptoms

B. Increase acid secretion C. Promote epithelial healing D. Prevent ulcer-related complications E. Prevent ulcer recurrence 15. Refractory peptic ulcers will most likely require which of the following interventions? A. An increase in the H 2 RA dose B. An evaluation of serum pepsin to exclude Zollinger-Ellison syndrome C. H. pylori testing if not done previously D. Combination therapy with an H 2 RA and PPI E. All of the above ANSWERS 1. A 2. D 3. A 4. D 5. C 6. D 7. C 8. D 9. E 10. D 11. C 12. B

13. D 14. B 15. C